Centre Amends Drugs Rules 1945, Key Amendments, Significance

With rapid advances in biotechnology and precision medicine, new therapies such as stem cell treatments, gene therapy and animal tissue transplants are becoming increasingly important in modern healthcare. Recognising the need for stronger regulation of these advanced technologies, the Central Government has amended the Drugs Rules, 1945 to bring Cell or Stem Cell-derived Products, Gene Therapeutic Products and Xenografts under the Centrally Licence Approving Authority (CLAA) framework. The amendment aims to ensure uniform regulation, improve patient safety and promote responsible innovation in India’s healthcare sector.

About the Drugs Rules, 1945

The Drugs Rules, 1945 were framed under the Drugs and Cosmetics Act, 1940 to regulate the manufacture, import, sale, distribution and licensing of drugs and cosmetics in India.

• The Rules provide the detailed procedures for implementing the provisions of the Drugs and Cosmetics Act, 1940.
• They prescribe standards for the manufacture, testing, storage, labelling, licensing and distribution of drugs, biological products and certain medical devices.
• The Rules aim to ensure that only safe, effective and quality medicines are made available to the public.
• They specify the roles and responsibilities of the Central and State Licensing Authorities in granting and monitoring licences.

The Rules are amended periodically to accommodate new medical technologies, strengthen regulation and align with evolving national and international standards.

Key Amendments to Drugs Rules, 1945

The amendment to the Drugs Rules, 1945 expands India’s regulatory framework by bringing advanced medical products under stricter and uniform regulatory oversight.

• Expanded the scope of CLAA: Cell or Stem Cell-derived Products, Gene Therapeutic Products and Xenografts have now been brought under the Centrally Licence Approving Authority (CLAA) framework.
  • Cell or Stem Cell-derived Products: Medicines developed from living cells or stem cells to repair or regenerate damaged tissues, such as stem cell therapy and CAR-T cell therapy.
  • Gene Therapeutic Products: Medicines that treat diseases by repairing, replacing or modifying defective genes, especially for genetic disorders and certain cancers.
  • Xenografts: Animal-derived tissues or organs, such as heart valves, that are transplanted into humans to replace damaged body parts.
  • The Centrally Licence Approving Authority (CLAA) is a regulatory mechanism under the Drugs and Cosmetics Act, 1940 through which the Central and State Licensing Authorities jointly regulate certain critical drugs and biological products.
• Joint regulation by Centre and States: These products will now be regulated jointly by the Central and State Licensing Authorities, ensuring better coordination in licensing, approval and monitoring across the country.
• Uniform regulatory standards: The amendment establishes common quality, safety and efficacy standards so that patients receive the same level of protection and treatment quality in every State.
• Enhanced regulatory scrutiny: Advanced therapies involving living cells, genes and animal tissues will now undergo more rigorous scientific evaluation, manufacturing inspections and safety assessments before approval.
• Expansion of the existing CLAA framework: Earlier, the CLAA framework covered vaccines, large-volume parenterals (IV fluids above 100 ml) and recombinant DNA (r-DNA) based medicines; the amendment expands this framework to include emerging medical technologies.
  • Recombinant DNA (r-DNA) medicines: Medicines produced using genetic engineering technology, such as insulin and certain monoclonal antibodies.

‹ ›

Why was this Amendment Needed?

The rapid growth of regenerative medicine and gene-based therapies has created new opportunities for treating diseases that were previously considered difficult or impossible to cure. However, these therapies also involve greater scientific complexity and potential risks.

• Advanced therapies involve living cells and genetic material, making their manufacturing and quality control much more complex than conventional medicines.
• Cell and gene therapies can produce long-term biological changes in the human body, making safety assessment more challenging.
• Increasing use of CAR-T cell therapy, stem cell therapy and gene editing has created the need for specialised regulatory mechanisms.
• Different licensing standards across States could lead to variations in quality and patient safety if a common regulatory framework is not adopted.
• Global regulatory agencies are strengthening oversight of advanced therapies, making it essential for India to align with international best practices.

Significance of the Amendment

The amendment strengthens India’s regulatory framework for advanced medical technologies while ensuring that innovation is balanced with patient safety and public health.

• Strengthens patient safety: Rigorous scientific evaluation and licensing will ensure that advanced therapies are safe, effective and of high quality before reaching patients.
• Ensures uniform regulation across India: Bringing these products under the CLAA framework establishes common licensing, quality and safety standards across all States and Union Territories.
• Strengthens regulatory oversight: Joint regulation by the Central and State Licensing Authorities improves monitoring, inspection and enforcement for complex biological products.
• Facilitates faster adoption of advanced therapies: A clear regulatory pathway will enable safe introduction of innovative treatments such as stem cell therapies, gene therapies and xenografts into clinical practice.
• Promotes innovation and research: A transparent and predictable regulatory environment encourages research institutions, biotechnology companies and pharmaceutical industries to develop advanced therapies.
• Supports treatment of complex diseases: Improved regulation will facilitate wider availability of cutting-edge therapies for blood cancers, genetic disorders, cardiovascular diseases and orthopaedic conditions.
• Build Public Confidence: Strong regulatory standards increase trust among patients and healthcare professionals in the safety and reliability of emerging therapies.
• Aligns India with global best practices: The amendment modernises India’s regulatory framework in line with internationally accepted standards for regulating advanced biological and regenerative medicines.
• Boosts the biotechnology and life sciences sector: A robust regulatory system enhances India’s competitiveness, attracts investment and supports growth in biotechnology, regenerative medicine and pharmaceutical innovation.
• Contributes to public health security: Strong regulation ensures that emerging medical technologies are introduced responsibly while safeguarding public health and improving access to advanced healthcare.